NCT01692496 - Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 29, 2013

Primary Completion Date

March 31, 2018

Study Completion Date

March 2, 2018

Conditions

Advanced and / or Metastatic Liposarcoma

Interventions

DRUG

Pazopanib

Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.

Trial Locations (15)

28041

Hospital 12 de Octubre, Madrid

31008

Hospital de Navarra, Pamplona

33011

Hospital Central de Asturias, Oviedo

36204

Complejo Hospitalario Universitario de Vigo, Vigo

38320

Hospital Universitario de Canarias, San Cristóbal de La Laguna

41013

Hospital Universitario Virgen del Rocío, Seville

46009

Instituto Valenciano de Oncología, Valencia

50009

Hospital Miguel Servet, Zaragoza

D-10707

HELIOS Klinikum Berlin-Buch (Sarkomzentrum Berlin-Brandenburg), Berlin

D-45147

Universitätsklinikum EssenInnere Klinik (Tumorforschung), Essen

D-30625

Medizinische Hochschule Hannover (Zentrum Innere Medizin), Hanover

D-68169

Universitätsmedizin Mannheim (Sarkomzentrum), Manheim

D-80336

Klinikum Großhadern der LMU Universität München (Med. Klinik und Poliklinik II), Munich

08035

Hospital Vall d'Hebrón, Barcelona

07010

Hospital Universitari Son Espases, Palma de Mallorca